Anesthetic efficacies of dexmedetomidine versus remifentanil combined with propofol target-controlled infusion in endobronchial ultrasound-guided transbronchial needle aspiration

ZHU Hongwei,WU Jingxiang,XU Meiying

2013-01-01

Abstract:Objective To compare the anesthetic efficacies of dexmedetomidine versus remifentanil combined with propofol target-controlled infusion (TCI) in endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Methods Sixty patients undergoing EBUS-TBNA were randomly assigned to remifentanil group and dexmedetomidine group (n=30). In remifentanil group, 0.5 μg/kg remifentanil was injected slowly, followed by infusion at maintenance dose of 0.02 μg·kg-1·min-1. In dexmedetomidine group, 0.5 μg/kg dexmedetomidine was injected within 10 min, followed by infusion at maintenance dose of 0.2 μg·kg-1·h-1. The initial concentration of propofol TCI was 1.5 μg/mL for all patients, which was adjusted by the bispectral index (BIS) 40-50. The operation began until consciousness was lost. Heart rate (HR), mean arterial pressure (MAP), and pulse oxygen saturation (SpO2) were recorded before anesthesia (T0), before the examination after anesthesia (T1), when bronchoscope passed the glottis point (T2), when ultrasound probe was inserted (T3), at biopsy (T4) and after bronchoscope pulled out (T5). The incidence of adverse events, such as cough, restlessness, respiratory depression (respiratory frequency less than 10/min), and recovery time were also obtained. Results In remifentanil group, HR and MAP at T1 were significantly lower than those at T0 (both P<0.05), but in dexmedetomidine group, only HR at T1 was lower than that at T0 (P<0.05). HR at T2 in dexmedetomidine group was significantly lower than that in remifentanil group (P<0.05). SpO2 in dexmedetomidine group was significantly higher than that in remifentanil group from T1 to T5 (all P<0.05). There were no significant differences in terms of HR at T0, T3, T4 and T5, MAP from T0 to T5, or SpO2 at T0 between two groups (all P>0.05). The incidence of cough in dexmedetomidine group was significantly higher than that in remifentanil group (P<0.05), while the incidence of respiratory depression and hypoxemia in dexmedetomidine group was significantly lower than that in remifentanil group (both P<0.05). The recovery time in dexmedetomidine group was significantly longer than that in remifentanil group (P<0.05). Conclusion Both dexmedetomidine and remifentanil combined with propofol TCI can provide effective sedation for EBUS-TBNA. Moreover, dexmedetomidine is safer and more effective than remifentanil.